Subconjunctival aflibercept
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Corneal Neovascularization
Conditions
Corneal Neovascularization
Trial Timeline
Jun 1, 2013 → Oct 1, 2015
NCT ID
NCT01868360About Subconjunctival aflibercept
Subconjunctival aflibercept is a phase 1 stage product being developed by Regeneron Pharmaceuticals for Corneal Neovascularization. The current trial status is terminated. This product is registered under clinical trial identifier NCT01868360. Target conditions include Corneal Neovascularization.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01868360 | Phase 1 | Terminated |
Competing Products
12 competing products in Corneal Neovascularization